Ramucirumab
Class
VEGF inhibitors
Subclass
Anti-VEGF receptor 2 monoclonal antibodies
Generic name
Ramucirumab
Brand names
Cyramza®
Common formulations
Solution
Dosage and administration
Adults patients
HCC
Metastatic CRC
Non-small cell lung cancer in patients with ALK rearrangement • Metastatic
Indications for use
Labeled indications
Adults
Safety risks
Boxed warnings
Myocardial infarction
Contraindications
A known hypersensitivity to Ramucirumab
Gastric cancer, receiving concomitant chronic NSAID therapy, anti-platelet therapy (other than once-daily aspirin), or therapeutic anticoagulant therapy
Warnings and precautions
Hepatic encephalopathy
Hypertension
Hypothyroidism
Nephrotic syndrome
Posterior reversible encephalopathy syndrome
Specific populations
Renal impairment
eGFR 29-50 mL/min/1.73 m²
eGFR 15-29 mL/min/1.73 m²
eGFR < 15 mL/min/1.73 m²
Renal replacement therapy
Continuous renal replacement
Intermittent hemodialysis
Peritoneal dialysis
Hepatic impairment
Child-Pugh A (mild)
Child-Pugh B (moderate)
Child-Pugh C (severe)
Pregnancy and breastfeeding
Pregnancy
All trimesters
Breastfeeding
Use with caution during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Uncommon < 1%
Rare < 0.1%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource